On the other side, since IFN-α has been applied to MCL treatment [107,108], targeting the BACH1/ZBTB20/IFN-α regulatory axis may provide a novel therapeutic strategy against MCL. This evidence concerns the gene ZBTB20 and mantle cell lymphoma.